Results 161 to 170 of about 693,649 (301)

IFNγ regulates MR1 transcription and antigen presentation. [PDF]

Front Immunol
Huber ME, Larson EA, Lust TN, Heisler CM, Harriff MJ.   +4 more
europepmc   +1 more source

Aging Is a Key Driver for Adult Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley   +1 more source

Single-cell transcriptome revealed the aberrant keratinocytes activation in antigen presentation in atopic dermatitis. [PDF]

Ann Med
Liu WX, Cao Y, Chen YF, Lu YF, Xu CY, Zhai YH, Wang C, Cao Z.   +7 more
europepmc   +1 more source

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source

HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors. [PDF]

Sci Adv
Hwang D, Erdman MC, Adhikari S, Pantula R, Epstein K, Li P, Costabile F, Rotsides P, Wang CS, Sun SM, Fazelinia H, Spruce LA, Fugmann T, Rrustemi T, Soh WT, Farrel A, Want MY, Facciabene A, Mir M, Maris JM, Sgourakis NG.   +20 more
europepmc   +1 more source

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky, Cara Joyce, H. Jeremy Bockholt, Paul A. Rudnick, William H. Adams, Fiona McAllister, Justin W. Smock, Michael A. Newton, Jane S. Paulsen   +8 more
wiley   +1 more source

Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy. [PDF]

J Immunother Cancer
O'Melia MJ, Menzel L, Lei PJ, Zhou H, Zhang X, Contreras-Alvarado N, Rajotte JJ, Liu L, Nikmaneshi MR, Baish JW, Ubellacker JM, Boland GM, Cohen S, Padera TP, Munn LL.   +14 more
europepmc   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

DNA damage in macrophages drives immune autoreactivity via nuclear antigen presentation. [PDF]

Nat Aging
Niotis G, Arvanitaki ES, Theodorakis E, Schmalen A, Juretschke T, Argyros O, Tsolis KC, Bertsias G, Drakos E, Beli P, Garinis GA.   +10 more
europepmc   +1 more source

Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt, Marius Ygonia, Ali Manouchehrinia, Philippe Lefrançois, Ingrid Kockum, Adil Harroud   +5 more
wiley   +1 more source